HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hormonal contraception in women with endometriosis: a systematic review.

AbstractOBJECTIVE:
A systematic review was carried out of studies of women with endometriosis, to examine the evidence for efficacy of the use of hormonal contraception to improve disease-related pain and decrease postoperative risk of disease recurrence.
METHODS:
A search of the Medline/PubMed and Embase databases was performed to identify all published English language studies on hormonal contraceptive therapies (combined hormonal contraceptives [CHCs], combined oral contraceptives [COCs], progestin-only pills [POPs] and progestin-only contraceptives [POCs]) in women with a validated endometriosis diagnosis, in comparison with placebo, comparator therapies or other hormonal therapies. Main outcome measures were endometriosis-related pain (dysmenorrhoea, pelvic pain and dyspareunia), quality of life (QoL) and postoperative rate of disease recurrence during treatment.
RESULTS:
CHC and POC treatments were associated with clinically significant reductions in dysmenorrhoea, often accompanied by reductions in non-cyclical pelvic pain and dyspareunia and an improvement in QoL. Only two COC preparations (ethinylestradiol [EE]/norethisterone acetate [NETA] and a flexible EE/drospirenone regimen) demonstrated significantly increased efficacy compared with placebo. Only three studies found that the postoperative use of COCs (EE/NETA, EE/desogestrel and EE/gestodene) reduced the risk of disease recurrence. There was no evidence that POCs reduced the risk of disease recurrence.
CONCLUSIONS:
CHCs and POCs are effective for the relief of endometriosis-related dysmenorrhoea, pelvic pain and dyspareunia, and improve QoL. Some COCs decreased the risk of disease recurrence after conservative surgery, but POCs did not. There is insufficient evidence, however, to reach definitive conclusions about the overall superiority of any particular hormonal contraceptive.
AuthorsGiovanni Grandi, Fabio Barra, Simone Ferrero, Filomena Giulia Sileo, Emma Bertucci, Antonella Napolitano, Fabio Facchinetti
JournalThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception (Eur J Contracept Reprod Health Care) Vol. 24 Issue 1 Pg. 61-70 (Feb 2019) ISSN: 1473-0782 [Electronic] England
PMID30664383 (Publication Type: Journal Article, Systematic Review)
Chemical References
  • Androstenes
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
  • Drug Combinations
  • Progestins
  • drospirenone and ethinyl estradiol combination
  • norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination
  • Ethinyl Estradiol
  • Desogestrel
  • Norethindrone
Topics
  • Adult
  • Androstenes (therapeutic use)
  • Contraception (methods)
  • Contraceptives, Oral, Combined (therapeutic use)
  • Contraceptives, Oral, Hormonal (therapeutic use)
  • Desogestrel (therapeutic use)
  • Drug Combinations
  • Endometriosis (complications, drug therapy)
  • Ethinyl Estradiol (therapeutic use)
  • Female
  • Humans
  • Norethindrone (therapeutic use)
  • Pelvic Pain (drug therapy, etiology)
  • Progestins (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: